Zepbound (tirzepatide) is a dual GLP-1/GIP receptor agonist primarily approved for chronic weight management, and also for type 2 diabetes (as Mounjaro), working by enhancing insulin secretion, slowing gastric emptying, and reducing appetite
It works by mimicking the hormone glucagon-like peptide-1 (GLP-1), which is a natural hormone released in the gut after eating
Guigmiens glutatin liposomal se hace en los EE.UU
Editors Note: A previous version of this article included a statement that Brian Morrell attributed his positive test to a specific energy drink which has been removed from this updated article
EClinicalMedicine DOI:10.1016/j.eclinm.2026.104007 Abstract The effectiveness of glucagon-like peptide-1 receptor agonists (GLP-1RAs) on binge eating in patients with obesity: a systematic review and meta-analysis Background Glucagon-like peptide-1 receptor agonists (GLP-1RAs), widely used for weight management and type 2 diabetes, may reduce binge eating behaviours and body dissatisfaction, but there are concerns that they might increase eating restraint
This can lead to: Weakness Fatigue Slower metabolism Increased risk of weight regain later Protecting muscle is one of the most important parts of healthy medical weight loss
